Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $4,036.00 |
|---|---|
| Enterprise Value | $484,449.00 |
| Earnings per Share | $0 |
| Beta | -0.2 |
| Outstanding Shares | 40,363,822 |
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.95 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | 14.44 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, an...